BioCentury
ARTICLE | Clinical News

FDA accepts NDA from Acorda for PD candidate Inbrija

February 23, 2018 8:18 PM UTC

Acorda Therapeutics Inc. (NASDAQ:ACOR) said FDA accepted for review an NDA for Inbrija levodopa inhalation powder (CVT-301) to treat "off" periods in Parkinson's disease patients receiving a carbidopa/levodopa regimen. The PDUFA date is Oct. 5.

The NDA is based on data from the Phase III SPAN-PD trial and from two long-term safety studies in PD patients...

BCIQ Company Profiles

Acorda Therapeutics Inc.